Systematic review of immunosuppressant guidelines in the COVID-19 pandemic
Aims: Individuals taking immunosuppressants are at increased susceptibility to viral infections in general. However, due to the novel nature of the COVID-19, there is a lack of evidence about the specific risks of the disease in this patient group. This systematic review aims to summarize the curren...
Main Authors: | Fenella Barlow-Pay, Thura Win Htut, Mina Khezrian, Phyo Kyaw Myint |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2021-02-01
|
Series: | Therapeutic Advances in Drug Safety |
Online Access: | https://doi.org/10.1177/2042098620985687 |
Similar Items
-
Routine use of immunosuppressants is associated with mortality in hospitalised patients with COVID-19
by: Phyo K. Myint, et al.
Published: (2021-02-01) -
Clinical frailty scale as a point of care prognostic indicator of mortality in COVID-19: a systematic review and meta-analysis
by: Stavroula Kastora, et al.
Published: (2021-06-01) -
Challenges in managing immunosuppressive therapies for psoriasis during the COVID-19 pandemic
by: K. Desai, et al.
Published: (2020-05-01) -
COVID-19 in Immunosuppressed Children
by: Emanuele Nicastro, et al.
Published: (2021-04-01) -
Decision-Making in COVID-19 and Frailty
by: Susan Moug, et al.
Published: (2020-05-01)